Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Potential of boron neutron capture therapy (BNCT) for epithelioid sarcoma.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2025

Same author

Sex Differences in Outcomes After Contemporary Percutaneous Coronary Intervention: Insights From the PENDULUM Registry.

JACC. Asia·2025

Same author

Potential of boron neutron capture therapy (BNCT) for myxofibrosarcoma.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2024

Same author

Improvement in the neutron beam collimation for application in boron neutron capture therapy of the head and neck region.

Scientific reports·2022

Same author

Ion-pairing assemblies of heteroporphyrin-based π-electronic cation with various counteranions.

Chemical communications (Cambridge, England)·2022

Same author

Design of a filtration system to improve the dose distribution of an accelerator-based neutron capture therapy system.

Medical physics·2022

Search research articles

Related Experiment Video

Updated: Nov 21, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

BNCT for primary synovial sarcoma.

Takuya Fujimoto¹, Minoru Suzuki², Shigeyuki Kuratsu³

¹Department of Orthopaedic Surgery, Hyogo Cancer Center, Japan; Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Japan.

Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine

|January 14, 2021

Summary

This summary is machine-generated.

Boron neutron capture therapy (BNCT) shows promise for treating rare synovial sarcomas. This innovative approach enabled successful tumor resection and limb function preservation in a patient, highlighting BNCT as a potential adjuvant therapy.

Keywords:

(18)F-fluorodeoxyglucose positron emission tomography/computed tomography 4-borono-2-(18)F-fluoro-l-phenylalanine positron emission tomography/computed tomography Adjuvant therapy Biphasic subtype Boron neutron capture therapy (BNCT)Clinical treatment Ki-67 L-type amino acid transporter 1 Monophasic subtype Primary Synovial sarcoma p-borono-l-phenylalanine (BPA)

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

Related Experiment Videos

Last Updated: Nov 21, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

Area of Science:

Oncology
Radiation Oncology
Medical Physics

Background:

Synovial sarcoma is a rare soft tissue malignancy.
Novel therapeutic strategies are needed for effective treatment.
Patient refusal of surgery due to potential limb dysfunction necessitates alternative approaches.

Observation:

A 46-year-old female presented with primary monophasic synovial sarcoma of the left thigh, involving the sciatic nerve.
The patient received two cycles of Boron Neutron Capture Therapy (BNCT) as an alternative to surgery.
Tumor reduction was observed following BNCT.

Findings:

Complete resection of the reduced tumor was achieved post-BNCT.
The patient experienced no local recurrence and regained unassisted ambulation.
BNCT demonstrated potential as an adjuvant therapy for synovial sarcoma, preserving limb function.

Implications:

BNCT may offer a viable treatment option for patients with synovial sarcoma who are not candidates for or decline surgery.
Further clinical studies and data accumulation are required to establish the definitive efficacy of BNCT for synovial sarcoma.
This case suggests BNCT's role in improving oncological outcomes and quality of life in rare tumor management.